A paper, made visible
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
Abstract evidence1 comparisonAutomated source matching · not expert reviewed
This visual is not yet available
- Available sources do not yet support a numeric visual.
No supported comparison is available to draw
- The paper record remains available. Quantitative pictures appear only when their design, measures and sources are established.